Aclaris Therapeutics
(NASDAQ:ACRS)
$15.92
0.27[1.73%]
At close: Dec 6(Delayed 15-Minutes)
Get Real Time Here
$15.92
After Hours: 4:01PM EDT
Day Range15.31 - 16.2952 Wk Range9.26 - 18.96Open / Close15.57 / 15.92Float / Outstanding64.3M / 66.7M
Vol / Avg.362.2K / 354.5KMkt Cap1.1BP/E-50d Avg. Price16.18
Div / Yield-Payout Ratio-Total Float64.3MEPS-0.3

Aclaris Therapeutics Stock (NASDAQ:ACRS), Quotes and News Summary

Aclaris Therapeutics Stock (NASDAQ: ACRS) stock price, news, charts, stock research, profile.

Loading...
Day Range15.31 - 16.2952 Wk Range9.26 - 18.96Open / Close15.57 / 15.92Float / Outstanding64.3M / 66.7M
Vol / Avg.362.2K / 354.5KMkt Cap1.1BP/E-50d Avg. Price16.18
Div / Yield-Payout Ratio-Total Float64.3MEPS-0.3
Lisa Levin - Apr 26, 2022, 8:34AM
Globe Newswire - Aug 1, 2022, 7:00AM
Globe Newswire - Jun 27, 2022, 7:00AM
Globe Newswire - Feb 1, 2022, 4:01PM
Globe Newswire - Jan 11, 2022, 4:01PM
Seeking Alpha - Aug 1, 2022, 7:42AM
Seeking Alpha - May 9, 2022, 11:06AM
Seeking Alpha - Feb 23, 2022, 10:25AM
Seeking Alpha - Jan 11, 2022, 4:45PM
Sector: Health Care.Industry: Pharmaceuticals
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-02-23
REV
Q3 2022Est.ActualSurprise
EPS-0.400-0.300 0.1000
REV1.600M19.018M17.418M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy Aclaris Therapeutics (ACRS) stock?

A

You can purchase shares of Aclaris Therapeutics (NASDAQ: ACRS) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Aclaris Therapeutics's (ACRS) competitors?

Q

What is the target price for Aclaris Therapeutics (ACRS) stock?

A

The latest price target for Aclaris Therapeutics (NASDAQ: ACRS) was reported by Goldman Sachs on Thursday, December 1, 2022. The analyst firm set a price target for 25.00 expecting ACRS to rise to within 12 months (a possible 57.04% upside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Aclaris Therapeutics (ACRS)?

A

The stock price for Aclaris Therapeutics (NASDAQ: ACRS) is $15.92 last updated Today at December 6, 2022, 9:00 PM UTC.

Q

Does Aclaris Therapeutics (ACRS) pay a dividend?

A

There are no upcoming dividends for Aclaris Therapeutics.

Q

When is Aclaris Therapeutics (NASDAQ:ACRS) reporting earnings?

A

Aclaris Therapeutics’s Q4 earnings are confirmed for Thursday, February 23, 2023.

Q

Is Aclaris Therapeutics (ACRS) going to split?

A

There is no upcoming split for Aclaris Therapeutics.

Q

What sector and industry does Aclaris Therapeutics (ACRS) operate in?

A

Aclaris Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.